ZYME

Zymeworks Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $25.96
52-Week Range: $16.00 – $31.34
Market Cap: $1.80B
P/E (TTM): —
EPS (TTM): -2.02
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 22.36
PEG Ratio: —
Return on Equity: -72.31%
Return on Assets: -24.15%
Gross Margin: -246.66%
Operating Margin: -918.95%
Profit Margin: 0.00%
Current Ratio: 6.32
Debt/Equity: 0.20
Total Debt: $16.01M
Free Cash Flow: $-65.06M
Revenue Growth: -90.60%
Earnings Growth: —
Enterprise Value: $1.53B

ZYME Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$412.48M	$76.01M	$76.30M	$105.97M
Research & Development	$208.60M	$143.62M	$134.62M	$137.00M
Selling, General & Admin	$73.40M	$70.40M	$61.50M	$61.50M
Operating Expenses	$282.00M	$214.02M	$196.12M	$198.50M
Operating Income	$130.49M	-$138.01M	-$119.82M	-$92.53M
EBITDA	$142.49M	-$120.70M	-$108.62M	-$81.42M
Pretax Income	$135.23M	-$119.24M	-$116.61M	-$79.75M
Income Tax	$10.89M	-$568.00K	$6.08M	$1.38M
Net Income	$124.34M	-$118.67M	-$122.69M	-$81.13M
Diluted EPS	1.90	-1.72	-1.62	-1.08
Diluted Shares	65.25M	68.86M	75.88M	75.41M

ZYME Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$400.91M	$157.56M	$66.10M	$41.16M
Receivables	$33.40M	$19.48M	$55.81M	$4.64M
Current Assets	$544.71M	$412.93M	$300.45M	$248.77M
Total Assets	$648.73M	$580.88M	$463.09M	$346.53M
Current Liabilities	$95.63M	$55.76M	$88.29M	$42.32M
Total Debt	$28.11M	$26.72M	$18.51M	$18.27M
Total Liabilities	$155.77M	$116.07M	$124.32M	$78.03M
Retained Earnings	-$558.76M	-$677.44M	-$830.34M	-$953.16M
Shareholders' Equity	$492.96M	$464.81M	$338.77M	$268.50M
Working Capital	$449.08M	$357.16M	$212.16M	$206.45M

ZYME Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$144.11M	-$118.32M	-$110.06M	-$33.01M
Capital Expenditure	-$13.13M	-$4.08M	-$3.07M	-$2.35M
Free Cash Flow	$130.98M	-$122.40M	-$113.12M	-$35.36M
Depreciation & Amortisation	$12.00M	$17.30M	$11.19M	$11.11M
Stock-Based Compensation	$4.01M	$8.10M	$17.79M	$28.03M
Investing Cash Flow	-$53.85M	-$207.25M	$38.76M	$26.66M
Financing Cash Flow	$108.58M	$81.87M	-$20.44M	-$18.56M
Share Repurchases	$0.00	$0.00	-$30.05M	-$41.70M
Net Change in Cash	$198.84M	-$243.71M	-$91.74M	-$24.90M

ZYME Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$27.11M	$48.73M	$27.61M	$2.52M	$2.41M	$4.59M
Research & Development	$35.74M	$34.45M	$35.58M	$31.23M	$34.46M	$27.43M
Selling, General & Admin	$17.00M	$14.90M	$14.10M	$15.40M	$15.10M	$19.30M
Operating Expenses	$52.74M	$49.35M	$49.68M	$46.63M	$49.56M	$46.73M
Operating Income	-$25.63M	-$623.00K	-$22.06M	-$44.12M	-$47.15M	-$42.15M
EBITDA	-$18.84M	$5.34M	-$19.48M	-$42.11M	-$41.44M	-$36.74M
Pretax Income	-$22.14M	$2.13M	-$18.27M	-$41.48M	-$46.35M	-$45.29M
Income Tax	$496.00K	-$186.00K	$1.34M	-$270.00K	-$2.19M	-$273.00K
Net Income	-$22.64M	$2.32M	-$19.60M	-$41.21M	-$44.16M	-$45.02M
Diluted EPS	-0.30	0.03	-0.26	-0.55	-0.59	-0.62
Diluted Shares	75.23M	77.38M	75.78M	75.34M	74.69M	72.99M

ZYME Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$76.20M	$98.25M	$64.83M	$41.16M	$244.28M	$179.41M
Receivables	$24.59M	$2.63M	$29.35M	$4.64M	$4.67M	$5.93M
Current Assets	$306.47M	$296.13M	$291.71M	$248.77M	$385.68M	$298.39M
Total Assets	$425.52M	$408.38M	$397.27M	$346.53M	$478.21M	$396.96M
Current Liabilities	$65.10M	$38.50M	$42.04M	$42.32M	$35.65M	$47.24M
Total Debt	$18.46M	$18.68M	$18.90M	$18.27M	$17.04M	$16.01M
Total Liabilities	$100.56M	$73.88M	$77.20M	$78.03M	$314.63M	$316.60M
Retained Earnings	-$852.97M	-$850.65M	-$886.47M	-$953.16M	-$1.07B	-$1.17B
Shareholders' Equity	$324.97M	$334.51M	$320.06M	$268.50M	$163.59M	$80.37M
Working Capital	$241.36M	$257.63M	$249.67M	$206.45M	$350.03M	$251.15M

ZYME Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.41M	$12.07M	-$31.41M	-$10.26M	-$45.72M	-$31.95M
Capital Expenditure	-$338.00K	-$884.00K	-$410.00K	-$720.00K	-$216.00K	—
Free Cash Flow	-$3.75M	$11.19M	-$31.82M	-$10.98M	-$45.93M	-$31.95M
Depreciation & Amortisation	$3.31M	$3.21M	$2.58M	$2.01M	$2.85M	$1.95M
Stock-Based Compensation	$6.40M	$5.87M	$6.91M	$8.85M	$6.93M	$11.33M
Investing Cash Flow	$12.18M	$8.74M	$368.00K	$5.37M	$69.96M	$17.07M
Financing Cash Flow	$1.32M	$1.32M	-$2.45M	-$18.74M	$178.79M	-$50.02M
Share Repurchases	$0.00	$0.00	-$16.22M	-$25.48M	-$76.15M	-$51.95M
Net Change in Cash	$10.09M	$22.14M	-$33.50M	-$23.63M	$203.03M	-$64.89M

Market Snapshot

About

Zymeworks is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics for cancer and other diseases. The company specializes in bispecific antibodies that can simultaneously engage two different targets, potentially offering improved efficacy over traditional antibody therapies. Zymeworks uses proprietary technology platforms to create differentiated therapeutic candidates.